# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-21-072479
Filing Date
2021-05-26
Accepted
2021-05-26 17:00:59
Documents
7
Period of Report
2021-07-19

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | tm2117172-1_pre14a.htm | PRE 14A | 643024
2 | GRAPHIC | lg_vynethera-4c.jpg | GRAPHIC | 481141
3 | GRAPHIC | sg_daviddomzalski-bw.jpg | GRAPHIC | 6648
4 | GRAPHIC | tm2117172d1-pc_proxy14c.jpg | GRAPHIC | 702082
5 | GRAPHIC | tm2117172d1-pc_proxy24c.jpg | GRAPHIC | 350737
6 | GRAPHIC | tm2117172d1-pc_proxy34c.jpg | GRAPHIC | 702975
7 | GRAPHIC | tm2117172d1-pc_proxy44c.jpg | GRAPHIC | 694220
| Complete submission text file | 0001104659-21-072479.txt |  | 4683222

Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38356 | Film No.: 21967197
SIC: 2834 Pharmaceutical Preparations